New drug cocktail shows promise against tough cancers
NCT ID NCT06247956
First seen Nov 01, 2025 · Last updated May 02, 2026 · Updated 25 times
Summary
This study tests a combination of three treatments—SHR-8068, adebrelimab, and chemotherapy—as a first-line therapy for people with advanced gastric or esophageal cancer that cannot be removed by surgery. The main goal is to see how many patients' tumors shrink significantly. About 153 adults aged 18-75 are participating in this phase 2 trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED GASTRIC ADENOCARCINOMA AND ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chinese PLA General Hospital
Beijing, Beijing Municipality, 100853, China
Conditions
Explore the condition pages connected to this study.